Description
Budesonide is a corticosteroid with strong glucocorticoid and weak mineralocorticoid characteristics. Budesonide exhibits anti-inflammatory and anti-asthma activities and is used clinically to treat Crohn’s disease, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disorder (COPD). In animal models, budesonide induces pulmonary vasoconstriction. Budesonide inhibits expression of IL-32 in lungs and improves pulmonary function in animal models of cigarette smoking-induced COPD. Additionally, budesonide decreases TGF-β1-induced VEGF secretion and activation of ERK and Smad3 in lung fibroblasts. Budesonide also induces DNA hypermethylation.
References
Deng X, Zhang Z, Gu W, et al. Budesonide inhibits interleukin-32 expression in a rat model of chronic obstructive pulmonary disease. Exp Lung Res. 2012 Aug;38(6):295-301. PMID: 22646473.
Orta ML, Domínguez I, Pastor N, et al. The role of the DNA hypermethylating agent Budesonide in the decatenating activity of DNA topoisomerase II. Mutat Res. 2010 Dec 10;694(1-2):45-52. PMID: 20883705.
Chen YJ, Wang T, Liu DS, et al. Effect of budesonide on TGF-beta1-enhanced VEGF production by lung fibroblasts. Cell Biol Int. 2010 Jul;34(7):777-82. PMID: 20359293.
Ewing P, Ryrfeldt A, Sjöberg CO, et al. Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung. Pulm Pharmacol Ther. 2010 Feb;23(1):9-14. PMID: 19800019.
